Focusing on patient 19 with a time lapse of 14.4 years from diagnosis to RT (Fig. 3b), the RT subclone (subclone 5) at transformation (T6) carried CDKN2A/B and TP53 (p.G245D) alterations, whereas the main CLL subclones driving the relapse after therapy at T4 and T5 harbored a different TP53 mutation (p.I195T; subclones 3 and 4). Here, CDKN2A is linked to B-cell chronic lymphocytic leukemia.